| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
The new wholly owned subsidiary will screen for rare disease therapeutics.
NEW YORK, Oct. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases.
Hoth will form and operate a new wholly owned subsidiary named Merveille.ai, which will focus on screening for collaborative opportunities utilizing Artificial Intelligence in the field of drug discovery.
Robb Knie, Chief Executive Officer of Hoth, stated, "We believe our current pipeline might have new unscreened opportunities to help patients dealing with rare diseases. We hope to utilize AI to further enhance our pipeline and partnering opportunities."
Posted In: HOTH
